Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials. These programs explore combinations of targeted therapy and standard chemotherapy in colorectal, ovarian and breast cancers. Allarity’s diagnostic platform supports these efforts by employing gene expression signatures to match treatments with tumor biology, offering a more personalized approach than conventional “one‐size‐fits‐all” regimens.

Founded in 2015 as OncoBay, the company rebranded to Allarity Therapeutics in 2020 to reflect its expanded precision medicine strategy. Headquartered in Copenhagen, Denmark, Allarity maintains a U.S. presence in Cambridge, Massachusetts, to facilitate clinical collaborations and regulatory interactions. Under the leadership of CEO Christian M. Vedelsdal and an experienced executive team, the company has built partnerships with research institutions and contract organizations to advance its clinical programs.

Allarity serves global markets by enrolling patients across North America and Europe in its ongoing trials. The company’s outward focus on combining diagnostics with therapeutics aligns with an evolving industry trend toward more targeted and data‐driven drug development, positioning Allarity to address significant unmet needs in oncology with a precision‐guided approach.

Key Stats

• Today's Range: $1.53 to $1.63
• 50-Day Range: $0.87 to $1.97
• 52-Week Range: $0.61 to $2.35
• Volume: 312,313 shs
• Average Volume: 3.58 million shs
• Market Capitalization: $23.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.25
• Consensus Rating: Buy

Allarity Therapeutics Stock Analysis - MarketRank™

Allarity Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 398th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Allarity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Allarity Therapeutics has a consensus price target of $9.25, representing about 471.0% upside from its current price of $1.62.

Amount of Analyst Coverage

Allarity Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allarity Therapeutics are expected to grow in the coming year, from ($78.08) to ($46.85) per share.

Price to Book Value per Share Ratio

Allarity Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.58% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently decreased by 83.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allarity Therapeutics does not currently pay a dividend.

Dividend Growth

Allarity Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.58% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently decreased by 83.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.52

News Sentiment

Allarity Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

20 people have searched for ALLR on MarketBeat in the last 30 days. This is an increase of 122% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.08% of the stock of Allarity Therapeutics is held by insiders.

Percentage Held by Institutions

Only 11.53% of the stock of Allarity Therapeutics is held by institutions.

ALLR Stock Analysis - Frequently Asked Questions

How have ALLR shares performed this year?

Allarity Therapeutics' stock was trading at $1.17 at the start of the year. Since then, ALLR shares have increased by 38.5% and is now trading at $1.62.

How were Allarity Therapeutics' earnings last quarter?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced its quarterly earnings results on Friday, August, 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06.

When did Allarity Therapeutics' stock split?

Allarity Therapeutics shares reverse split on Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How will Allarity Therapeutics' stock buyback program work?

Allarity Therapeutics' Board of Directors authorized a stock buyback plan on Monday, March 3rd 2025, which allows the company to buy back $5,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 128.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allarity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Cara Therapeutics (CARA), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE).

Company Calendar

• Last Earnings: 8/15/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Allarity Therapeutics: $9.25
• High Price Target: $9.25
• Low Price Target: $9.25
• Potential Upside/Downside: +487.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -173.31%
• Return on Assets: -102.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.31
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.62 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 14,520,000
• Free Float: 14,512,000
• Market Cap: $22.87 million
• Optionable: Not Optionable
• Beta: 0.22